Compare DINO & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DINO | CYTK |
|---|---|---|
| Founded | 1947 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | DINO | CYTK |
|---|---|---|
| Price | $46.16 | $63.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $59.40 | ★ $82.38 |
| AVG Volume (30 Days) | ★ 2.8M | 2.1M |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.34% | N/A |
| EPS Growth | ★ 21.43 | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $26,905,000,000.00 | $87,211,000.00 |
| Revenue This Year | N/A | $346.43 |
| Revenue Next Year | $2.10 | $57.69 |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | ★ 2609.26 |
| 52 Week Low | $24.66 | $29.31 |
| 52 Week High | $56.58 | $70.98 |
| Indicator | DINO | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 31.39 | 51.81 |
| Support Level | $45.71 | $60.42 |
| Resistance Level | $48.31 | $65.28 |
| Average True Range (ATR) | 1.03 | 2.65 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 10.21 | 37.38 |
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.